Linked Life Data

14695662

Source:http://linkedlifedata.com/resource/pubmed/id/14695662

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14695662rdf:typepubmed:Citationlld:pubmed
pubmed-article:14695662lifeskim:mentionsumls-concept:C0019169lld:lifeskim
pubmed-article:14695662lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:14695662lifeskim:mentionsumls-concept:C0080103lld:lifeskim
pubmed-article:14695662lifeskim:mentionsumls-concept:C1332717lld:lifeskim
pubmed-article:14695662lifeskim:mentionsumls-concept:C1706438lld:lifeskim
pubmed-article:14695662lifeskim:mentionsumls-concept:C0039194lld:lifeskim
pubmed-article:14695662lifeskim:mentionsumls-concept:C0085358lld:lifeskim
pubmed-article:14695662lifeskim:mentionsumls-concept:C0524909lld:lifeskim
pubmed-article:14695662lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:14695662lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:14695662lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:14695662lifeskim:mentionsumls-concept:C1413244lld:lifeskim
pubmed-article:14695662lifeskim:mentionsumls-concept:C2698600lld:lifeskim
pubmed-article:14695662lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:14695662lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:14695662lifeskim:mentionsumls-concept:C0444669lld:lifeskim
pubmed-article:14695662lifeskim:mentionsumls-concept:C0280274lld:lifeskim
pubmed-article:14695662lifeskim:mentionsumls-concept:C1512948lld:lifeskim
pubmed-article:14695662lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:14695662lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:14695662pubmed:issue2lld:pubmed
pubmed-article:14695662pubmed:dateCreated2003-12-25lld:pubmed
pubmed-article:14695662pubmed:abstractTextRecognition of HBV-infected hepatocytes by CD8 T-lymphocytes is important for viral clearance. Expression of hepatitis B core antigen (HBcAg) in HBV-infected hepatocytes can trigger this antiviral T-cell response. The intrahepatic CD8 T-lymphocytes and HBcAg expression were investigated in relation to response to antiviral therapy. Forty chronic HBeAg-positive patients treated with either lamivudine (n = 20) or interferon-alpha (n = 20) were investigated. Ten patients from each treatment group exhibited a response. Liver biopsies were carried out before and after therapy. CD8 T-lymphocytes and HBcAg expression were detected by immunohistochemistry. The number of pretreatment intrahepatic CD8 T-lymphocytes was significantly higher in responders (P = 0.008). In responders baseline nuclear HBcAg expression tended to be lower (P = 0.09). Cytoplasmic expression was not significantly different between responders and non-responders (P = 0.46). The number of CD8 T-lymphocytes correlated with cytoplasmic HBcAg (r(s) = 0.31; P = 0.04); CD8 T-lymphocytes were situated in clusters of hepatocytes with cytoplasmic HBcAg. Longitudinal analysis showed a significant reduction of CD8 T-lymphocytes after treatment in responders (P < 0.001). Multivariate analysis revealed pretreatment CD8 T-lymphocytes and age as independent prognostic factors for response (n = 40). The number of pretreatment CD8 T-lymphocytes was the only independent prognostic indicator for response to interferon-alpha (P = 0.03); it was of borderline significance for lamivudine therapy (P = 0.06). It is concluded that the number of pretreatment intrahepatic CD8 T-lymphocytes is an important predictor of response to HBV therapy with either interferon-alpha or lamivudine. Response to therapy led to a significant reduction of intrahepatic CD8 T-lymphocytes. Co-localisation of CD8 T-lymphocytes and HBcAg-positive hepatocytes suggests antiviral activity predominantly at the site of maximum HBV replication.lld:pubmed
pubmed-article:14695662pubmed:languageenglld:pubmed
pubmed-article:14695662pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14695662pubmed:citationSubsetIMlld:pubmed
pubmed-article:14695662pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14695662pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14695662pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14695662pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14695662pubmed:statusMEDLINElld:pubmed
pubmed-article:14695662pubmed:monthFeblld:pubmed
pubmed-article:14695662pubmed:issn0146-6615lld:pubmed
pubmed-article:14695662pubmed:authorpubmed-author:KustersJohann...lld:pubmed
pubmed-article:14695662pubmed:authorpubmed-author:HopWim C JWClld:pubmed
pubmed-article:14695662pubmed:authorpubmed-author:de...lld:pubmed
pubmed-article:14695662pubmed:authorpubmed-author:SchalmSolko...lld:pubmed
pubmed-article:14695662pubmed:authorpubmed-author:KwekkeboomJaa...lld:pubmed
pubmed-article:14695662pubmed:authorpubmed-author:JanssenHarry...lld:pubmed
pubmed-article:14695662pubmed:authorpubmed-author:van der...lld:pubmed
pubmed-article:14695662pubmed:authorpubmed-author:TangThjon JTJlld:pubmed
pubmed-article:14695662pubmed:copyrightInfoCopyright 2004 Wiley-Liss, Inc.lld:pubmed
pubmed-article:14695662pubmed:issnTypePrintlld:pubmed
pubmed-article:14695662pubmed:volume72lld:pubmed
pubmed-article:14695662pubmed:ownerNLMlld:pubmed
pubmed-article:14695662pubmed:authorsCompleteYlld:pubmed
pubmed-article:14695662pubmed:pagination215-22lld:pubmed
pubmed-article:14695662pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:14695662pubmed:meshHeadingpubmed-meshheading:14695662...lld:pubmed
pubmed-article:14695662pubmed:meshHeadingpubmed-meshheading:14695662...lld:pubmed
pubmed-article:14695662pubmed:meshHeadingpubmed-meshheading:14695662...lld:pubmed
pubmed-article:14695662pubmed:meshHeadingpubmed-meshheading:14695662...lld:pubmed
pubmed-article:14695662pubmed:meshHeadingpubmed-meshheading:14695662...lld:pubmed
pubmed-article:14695662pubmed:meshHeadingpubmed-meshheading:14695662...lld:pubmed
pubmed-article:14695662pubmed:meshHeadingpubmed-meshheading:14695662...lld:pubmed
pubmed-article:14695662pubmed:meshHeadingpubmed-meshheading:14695662...lld:pubmed
pubmed-article:14695662pubmed:meshHeadingpubmed-meshheading:14695662...lld:pubmed
pubmed-article:14695662pubmed:meshHeadingpubmed-meshheading:14695662...lld:pubmed
pubmed-article:14695662pubmed:meshHeadingpubmed-meshheading:14695662...lld:pubmed
pubmed-article:14695662pubmed:meshHeadingpubmed-meshheading:14695662...lld:pubmed
pubmed-article:14695662pubmed:meshHeadingpubmed-meshheading:14695662...lld:pubmed
pubmed-article:14695662pubmed:meshHeadingpubmed-meshheading:14695662...lld:pubmed
pubmed-article:14695662pubmed:meshHeadingpubmed-meshheading:14695662...lld:pubmed
pubmed-article:14695662pubmed:meshHeadingpubmed-meshheading:14695662...lld:pubmed
pubmed-article:14695662pubmed:year2004lld:pubmed
pubmed-article:14695662pubmed:articleTitleIntrahepatic CD8 T-lymphocytes and HBV core expression in relation to response to antiviral therapy for chronic hepatitis B patients.lld:pubmed
pubmed-article:14695662pubmed:affiliationDepartment of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, The Netherlands.lld:pubmed
pubmed-article:14695662pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14695662pubmed:publicationTypeClinical Triallld:pubmed